Pennsylvania Headache Center- PHC

Pennsylvania Headache Center- PHC PHC is a non-narcotic, headache center founded by author and clinician-scientist, Dr. Lee Peterlin.

PHC is dedicated to improving the lives of those with headache disorders.

07/23/2025

STROKE NOT INCREASED WITH HORMONAL CONTRACEPTION

Unnecessary confusion still surrounds the use of combined hormonal contraceptives (CHCs) in the setting of migraine and particularly in those with migraine with aura (MwA).

Despite new data from studies that consistently show that stroke risk is not increased with today's very low dose combined hormonal contraception containing 20-25 µg ethinyl estradiol (EE), contraceptive use, however, is still restricted by some clinicians and guidelines. And this restriction is largely due to concerns of increased stroke risk.

In the era of hormonal contraception containing 20-25 µg ethinyl estradiol (EE) such concerns are antiquated and originated from data published over half a century ago (in the era of HIGH dose contraceptives) and ignore multiple newer studies.

It is time clinicians and guidelines revisit this and consider ALL the data including the CURRENT data on stroke with today's very low dose combined hormonal contraception containing 20-25 µg ethinyl estradiol (EE) - particularly for women with migraine.

Data show that stroke risk is not increased with today's very low dose combined hormonal contraception containing 20-25 µg ethinyl estradiol (EE).

07/23/2025

The Impact of Contraception on Migraine aura: a retrospective case series

In a study published in the journal Headache in 2012, Drs. Anne Calhoun, Sutapa Ford and Amy Pruitt evaluated if extended-cycle dosing of an ultralow dose vaginal ring contraceptive decreases frequency of migraine aura and prevents menstrual related migraine (MRM). Twenty-eight women met study criteria, none of whom were smokers.

Use of an extended-cycle vaginal ring contraceptive was associated with a reduced frequency of migraine aura and with resolution of MRM.

Classic Response for Novel Scientific Discoveries or Theories
07/07/2025

Classic Response for Novel Scientific Discoveries or Theories

"All truth passes through three stages. First, it is ridiculed. Second, it is violently opposed. Third, it is accepted as being self-evident." — Arthur Schopenhauer
Truth evolves through resistance to acceptance. Professionals championing truth foster resilience, driving progress by navigating skepticism and opposition in transformative landscapes.

05/06/2025

I HEREBY DECLARE THAT I DO NOT GIVE MY PERMISSION FOR FACEBOOK OR META TO USE ANY OF MY PERSONAL DATA.

04/23/2025

Episodic Migraine Risk Greater in Those with Obesity.

Multiple large epidemigical population studies have demonstrated that the risk of episodic migraine is nearly 30% higher in individuals with obesity.

04/11/2025

SKIPPING MEALS BAD FOR MIGRAINE

Did you know that skipping a meal or fasting is a more substantial trigger for migraines than individual foods?

Much thanks to our amazing patients & the great team at Pennsylvaniansa Headache Center who helped make this award possi...
04/08/2025

Much thanks to our amazing patients & the great team at Pennsylvaniansa Headache Center who helped make this award possible!

Almost 25% of Patients on Atogepant for Migraine Prevention Experienced a 7% or More Weight Loss After 52 Weeks of Use M...
12/09/2024

Almost 25% of Patients on Atogepant for Migraine Prevention Experienced a 7% or More Weight Loss After 52 Weeks of Use

Migraine, whether episodic or chronic, is comorbid with obesity. Atogepant is a CGRP receptor antagonist that is associated with modest weight loss. In the most recent publication of Cephalalgia, weight loss in participants taking atogepant for migraine prevention was evaluated.

Weight loss was observed beginning at week 2 of daily use of atogepant, which reached to a 2% weight loss after 40 weeks. In the pooled long-term safety trials of atogepant lasting over a year (up to 16 months), 24% of participants on atogepant 60 mg per day experienced a 7% or more weight loss, as compared to just under 15% of those given placebo.

09/07/2024

Targeting pituitary adenylate cyclase–activating polypeptide (PACAP) is a new avenue for treating migraine. The efficacy and safety of intravenous Lu AG09222, a humanized monoclonal antibody direct...

09/04/2024

BETA-BLOCKERS MAY BE TROUBLE IN SERVICES MEMBERS WITH MIGRAINE

In modern warfare, the primary causes of unit attrition have never been combat injuries. In fact, in both World Wars I and II, respiratory and infectious disorders were ranked as the top two causes of hospitalizations. Neurological disorders, including headache, ranked fifth. In Operations Iraqi Freedom and Enduring freedom, non-battle musculoskeletal injuries accounted for more injuries than any other injuries; however neurological illness - including headache - rose to the second leading cause of non-combat-related unit attrition.

Migraine is common in service members. In the U.S. migraine occurs in 10-15% of the general population and rises up to 30% in U.S. service members. Furthermore, almost 25% of migraineurs with post-traumatic stress disorder (PTSD) report combat as the most significant traumatic life even associated with their PTSD.

(Note: Post-traumatic stress disorder (PTSD) occurs as a result of exposure to extreme traumatic stressors that arouse feelings of intense fear, helplessness, and horror. As a result of these stressors the individual’s response characteristically involves re-experiencing the event emotionally, numbing or flattening of affect, and avoidance of stimuli that are associated with the event and increased arousal.)

PTSD is common in service members and in those with migraine. While PTSD occurs in about 8% of the general population, PTSD has been estimated to occur in 30% of those with migraine, 20% of service members not seeking treatment, and up to 50% in service members seeking treatment.

The high prevalence rate of migraine in service members and the strong association between migraine and PTSD, should be given serious consideration, particularly in regards to those being considered for return to combat. In a study led by Dr. Steve Cohen at Johns Hopkins, the use of beta-blockers was the factor most strongly associated with a failure to return to duty, even more so than opioid use and traumatic brain injury. It has been hypothesized that that this may be due greater disease burden from the medical indications triggering the use of beta blockers (e.g. migraine, PTSD, hypertension) OR even the medication itself (i.e. beta-blockers) which predispose the patients to even greater vulnerability to develop PTSD. Regardless of the reason for the use of beta blockers being associated with failure to return to duty, it is important for clinicians treating migraine, and service members seeking care for migraine, to consider migraine preventives other than beta-blockers for migraine prevention.

Peterlin et al. Cephalalgia. 2011;31(2):235–244. Post-traumatic stress disorder, drug abuse and migraine: New findings from the National Comorbidity Survey Replication(NCS-R)
Peterlin BL, Williams MA, Rapoport AM. Comment on : Headaches during war: analysis of presentation, treatment, and factors associated with outcome. (Letter to the Editor) Cephalalgia 2012;Oct;32(13):1009-10. [Commentary]
Cohen SP et al. Headache during war: analysis of presentation, treatment, and factors associated with outcome. Cephalalgia 2012;32(2):94-108
Ramchand et al. Disparate prevalence estimates of PTSD among service members who served in Iraq and Afghanistan: possible explanations. J Trauma Stress 2010;23(1):59-68.

PHC is a non-narcotic, headache center founded by author and clinician-scientist, Dr. Lee Peterlin. PHC is dedicated to improving the lives of those with headache disorders.

Check out Laura Nozicka's podcast "Desperate For a Diagnosis" podcast which just came out! She sat down with Dr. Peterli...
08/13/2024

Check out Laura Nozicka's podcast "Desperate For a Diagnosis" podcast which just came out! She sat down with Dr. Peterlin for an interview on challenges in recognizing and treating migraine. Here is a link to the podcast on youtube:
https://www.youtube.com/watch?v=84S3wtMLwRI

If you are interested in checking out this one or past podcasts from Laura, you can find her on linkedin or youtube or visit her website at www.desperateforadiagnois.com.

In this episode of the Desperate for a Diagnosis podcast, host Laura Nozicka engages in a comprehensive discussion with Dr. Lee Peterlin, a distinguished cli...

Dr. Jennifer Haythornthwaite, PhD, received the John D. Loeser Prize for Distinguished Lifetime Achievement in the Clini...
08/08/2024

Dr. Jennifer Haythornthwaite, PhD, received the John D. Loeser Prize for Distinguished Lifetime Achievement in the Clinical Science of Pain at the IASP 2024 World Congress on Pain in Amsterdam today. Her lecture discussed how our thoughts influence pain, particularly how the brain and the experience of pain are changed by past experiences and the anticipation of pain.

Address

205 Grandview Avenue, #206
Wormleysburg, PA
17011

Opening Hours

Monday 9am - 4pm
Tuesday 9am - 4pm
Wednesday 9am - 4pm
Thursday 9am - 4pm

Telephone

+17177456223

Alerts

Be the first to know and let us send you an email when Pennsylvania Headache Center- PHC posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share